Inmazeb (in combination with atoltivimab and odesivimab)
E1361798
UNEXPLORED
Inmazeb is an FDA-approved antibody cocktail therapy used to treat infections caused by Zaire ebolavirus.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Inmazeb (in combination with atoltivimab and odesivimab) canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T19157622 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Inmazeb (in combination with atoltivimab and odesivimab) Context triple: [maftivimab, isMarketedAs, Inmazeb (in combination with atoltivimab and odesivimab)]
-
A.
odesivimab
Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
B.
maftivimab
Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
C.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
D.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
E.
ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Inmazeb (in combination with atoltivimab and odesivimab) Target entity description: Inmazeb is an FDA-approved antibody cocktail therapy used to treat infections caused by Zaire ebolavirus.
-
A.
odesivimab
Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
B.
maftivimab
Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
C.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
D.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
E.
ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.